When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Professor Li Zhang, Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong, and co-authors, have published research in Advanced Functional Materials on a polyvinyl alcohol…
A recent publication in Interventional Pain Medicine, authored by Rohan Jotwani, MD, MBA, of Brigham and Women’s Hospital, Harvard Medical School in Boston, MA, and colleagues, demonstrates the…
